Molecular docking, 3D-QSAR and simulation studies for identifying pharmacophoric features of indole derivatives as 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) inhibitors

References

• Azam, M. A., Thathan, J., & Jupudi, S. (2020). Pharmacophore modeling, atom based 3D-QSAR, molecular docking and molecular dynamics studies on Escherichia coli ParE inhibitors. Computational Biology and Chemistry, 84, 107197. https://doi.org/10.1016/j.compbiolchem.2019.107197
   PubMed Web of Science ®Google Scholar
• Azami, H., Abe, T., Kakefuda, A., Kondoh, Y., Watanabe, K., Kamikawa, A., & Yasuda, M. (2010). Indole Compound (Patent No. WO2010101127).
   Google Scholar
• Byrns, M. C., Duan, L., Lee, S. H., Blair, I. A., & Penning, T. M. (2010). Aldo-Keto reductase 1C3 expression in MCF-7 cells reveals roles in steroid hormone and prostaglandin metabolism that may explain its over-expression in breast cancer. The Journal of Steroid Biochemistry and Molecular Biology, 118(3), 177–187. https://doi.org/10.1016/j.jsbmb.2009.12.009
   PubMed Web of Science ®Google Scholar
• Chung, J. Y., Pasha, F., Cho, S. J., Won, M., Lee, J. J., & Lee, K. (2009). Pharmacophore-based 3D-QSAR of HIF-1 inhibitors. Archives of Pharmacal Research, 32(3), 317–323. https://doi.org/10.1007/s12272-009-1301-3
   PubMed Web of Science ®Google Scholar
• Endo, S., Oguri, H., Segawa, J., Kawai, M., Hu, D., Xia, S., Okada, T., Irie, K., Fujii, S., & Gouda, H. (2020). Development of novel AKR1C3 inhibitors as new potential treatment for castration-resistant prostate cancer. Journal of Medicinal Chemistry, 63(18), 10396–10411.
   PubMed Web of Science ®Google Scholar
• Gholami Rostami, E., & Fatemi, M. H. (2018). Comparative molecular field analysis and hologram quantitative structure activity relationship studies of pyrimidine series as potent phosphodiesterase 10A inhibitors. Journal of the Chinese Chemical Society, 65(11), 1293–1306.
   Web of Science ®Google Scholar
• Gholami Rostami, E., & Fatemi, M. H. (2019). Molecular docking and teceptor-based QASR studies on pyrimidine derivatives as potential phosphodiesterase 10A inhibitors. Structural Chemistry, 30(6), 2347–2368.
   Web of Science ®Google Scholar
• Halder, A. K., Saha, A., Saha, K. D., & Jha, T. (2015). Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation. Journal of Biomolecular Structure & Dynamics, 33(8), 1756–1779. https://doi.org/10.1080/07391102.2014.969772
   PubMed Web of Science ®Google Scholar
• Hall, D. C. Jr, & Ji, H.-F. (2020). A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease. Travel Medicine and Infectious Disease, 35, 101646.
   PubMed Web of Science ®Google Scholar
• Harris, G. S., & Kozarich, J. W. (1997). Steroid 5α-reductase inhibitors in androgen-dependent disorders. Current Opinion in Chemical Biology, 1(2), 254–259. https://doi.org/10.1016/s1367-5931(97)80017-8
   PubMed Web of Science ®Google Scholar
• Kakefuda, A., Kondoh, Y., Hirano, M., Kamikawa, A., Enjo, K., & Furutani, T. (2008). Benzimidazole derivative (Patent No. WO2009014150).
   Google Scholar
• Loschwitz, J., Jäckering, A., Keutmann, M., Olagunju, M., Olubiyi, O. O., & Strodel, B. (2021). Dataset of AMBER force field parameters of drugs, natural products and steroids for simulations using GROMACS. Data in Brief, 35, 106948. https://doi.org/10.1016/j.dib.2021.106948
   PubMed Web of Science ®Google Scholar
• Marnett, L. J., Liedtke, A. J., Penning, T. M., Adeniji, A. O., & Byrns, M. C. (2013). Indomethacin Analogs for the Treatment of Castrate-Resistant Prostate Cancer (Patent No. WO2013059245).
   Google Scholar
• Miller, B. R., III, McGee, Jr, T. D., Swails, J. M., Homeyer, N., Gohlke, H., & Roitberg, A. E. (2012). MMPBSA. py: An efficient program for end-state free energy calculations. Journal of Chemical Theory and Computation, 8(9), 3314–3321.
   PubMed Web of Science ®Google Scholar
• Mousavi, S. F., & Fatemi, M. H. (2019). Probing the binding mechanism of capecitabine to human serum albumin using spectrometric methods, molecular modeling, and chemometrics approach. Bioorganic Chemistry, 90, 103037. https://doi.org/10.1016/j.bioorg.2019.103037
   PubMed Web of Science ®Google Scholar
• Niimi, T., Kamikawa, A., Amano, Y., Yamaguchi, T., Suzumura, K., Enjo, K., Furutani, T., Kakefuda, A., Kondoh, Y., & Hirano, M. (2007). 17b-HSD Type 5 Inhibitor (Patent No. WO2007100066).
   Google Scholar
• Olotu, F. A., Omolabi, K. F., & Soliman, M. E. (2021). Piece of the puzzle: Remdesivir disassembles the multimeric SARS-CoV-2 RNA-dependent RNA polymerase complex. Cell Biochemistry and Biophysics, 79(2), 175–187. https://doi.org/10.1007/s12013-021-00977-y
   PubMed Web of Science ®Google Scholar
• Ounissi, M., Kameli, A., Tigrine, C., & Rachedi, F. Z. (2018). Computer-aided identification of natural lead compounds as cyclooxygenase-2 inhibitors using virtual screening and molecular dynamic simulation. Computational Biology and Chemistry, 77, 1–16. https://doi.org/10.1016/j.compbiolchem.2018.07.005
   PubMed Web of Science ®Google Scholar
• Poirier, D. (2010). 17β-hydroxysteroid dehydrogenase inhibitors: A patent review. Expert Opinion on Therapeutic Patents, 20(9), 1123–1145. https://doi.org/10.1517/13543776.2010.505604
   PubMed Web of Science ®Google Scholar
• Rajan, R. K., Kumar, S. S. M., & Balaji, B. (2017). Soy isoflavones exert beneficial effects on letrozole-induced rat polycystic ovary syndrome (PCOS) model through anti-androgenic mechanism. Pharmaceutical Biology, 55(1), 242–251.
   PubMed Web of Science ®Google Scholar
• Singh, Y., Sanjay, K. S., Kumar, P., Singh, S., & Thareja, S. (2022). Molecular dynamics and 3D-QSAR studies on indazole derivatives as HIF-1α inhibitors. Journal of Biomolecular Structure and Dynamics, 1–18. https://doi.org/10.1080/07391102.2022.2051745
   PubMedGoogle Scholar
• Valdés-Tresanco, M. S., Valdés-Tresanco, M. E., Valiente, P. A., & Moreno, E. (2021). gmx_MMPBSA: A new tool to perform end-state free energy calculations with GROMACS. Journal of Chemical Theory and Computation, 17(10), 6281–6291. https://doi.org/10.1021/acs.jctc.1c00645
   PubMed Web of Science ®Google Scholar
• Vanajothi, R., Hemamalini, V., Jeyakanthan, J., & Premkumar, K. (2020). Ligand-based pharmacophore mapping and virtual screening for identification of potential discoidin domain receptor 1 inhibitors. Journal of Biomolecular Structure & Dynamics, 38(9), 2800–2808. https://doi.org/10.1080/07391102.2019.1640132
   PubMed Web of Science ®Google Scholar
• Watanabe, K., Kakefuda, A., Yasuda, M., Enjo, K., Kikuchi, A., Furutani, T., Naritomi, Y., Otsuka, Y., Okada, M., & Ohta, M. (2013). Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl) carbonyl] piperidin-4-yl} propan-2-ol: A novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor. Bioorganic & Medicinal Chemistry, 21(17), 5261–5270. https://doi.org/10.1016/j.bmc.2013.06.025
   PubMed Web of Science ®Google Scholar
• Yadav, D. K., Sharma, P., Misra, S., Singh, H., Mancera, R. L., Kim, K., Jang, C., Kim, M.-H., Pérez-Sánchez, H., Choi, E. H., Kumar, S., & Saloni. (2018). Studies of the benzopyran class of selective COX-2 inhibitors using 3D-QSAR and molecular docking. Archives of Pharmacal Research, 41(12), 1178–1189., https://doi.org/10.1007/s12272-017-0945-7
   PubMed Web of Science ®Google Scholar
• Yepuru, M., Wu, Z., Kulkarni, A., Yin, F., Barrett, C. M., Kim, J., Steiner, M. S., Miller, D. D., Dalton, J. T., & Narayanan, R. (2013). Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth AKR1C3 is an AR coactivator. Clinical Cancer Research, 19(20), 5613–5625.
   PubMed Web of Science ®Google Scholar